Regulatory change can make or break a startup’s trajectory overnight. Dr Angela Jones, co-founder of Petscribers shares how the UK Competition and Markets Authority’s investigation into the veterinary sector validated their vision, flipped investor sentiment, and drove veterinary interest. 

Transitioning from stealth to commercial impact requires both capital and platform validation. Alexandros Pantalis, CEO of Phagos reflects on raising €25M Series A and the regulatory milestones that enabled first commercial sales of personalised phage-based veterinary medicines in France.

Partnerships can transform the trajectory of a health-tech startup. Johanna Majamaa, CEO of GekkoVet discusses how working with Royal Canin enabled the company to validate its platform across 100 clinics, demonstrate real-world impact, and lay the groundwork for expansion into new markets and universities.

High-quality data is increasingly central to drug discovery, yet much of it remains fragmented, difficult to interpret, and hard to translate into clear R&D decisions. Ruchi Sharma, CEO of Stemnovate, shares how the company has navigated data complexity across human and animal health to build reproducible, species-relevant models that support more informed drug discovery decisions.

Securing the right exit is critical to ensuring innovation achieves full market potential. Louise Grubb, Managing Director of TriviumVet, shares how the company balanced growth milestones, resisted low valuations, and leveraged regulatory success to secure the right partner at the right time to achieve sustainable scale post-acquisition.

Nutrition is emerging as a powerful tool for preventing disease and strengthening immunity in livestock. Changemakers leading this shift explore the opportunities and hurdles that will shape evidence generation, farmer adoption, and the scaling of preventative nutrition across global production systems.